According to Adial Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.0670968. At the end of 2022 the company had a P/E ratio of -0.0509.
Year | P/E ratio | Change |
---|---|---|
2022 | -0.0509 | -98.02% |
2021 | -2.57 | 30.08% |
2020 | -1.98 | -26.18% |
2019 | -2.68 | -5.51% |
2018 | -2.83 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
15.0 | 22,243.24% | ๐บ๐ธ USA | |
-3.33 | -5,067.94% | Bahamas |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.